Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2022) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

80O Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study

(2022) E. Felip et al.   ANNALS OF ONCOLOGY

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

(2022) Mary O’Brien et al.   LANCET ONCOLOGY

Curative-Intent Treatment with Durvalumab in Early-Stage Cancers

(2021) Giovanni Melillo et al.   ADVANCES IN THERAPY

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

(2021) Enriqueta Felip et al.   LANCET

Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non‐small cell lung cancer treated with adjuvant therapies in a community oncology setting: A real‐world retrospective observational study

(2021) Beilei Cai et al.   Thoracic Cancer

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

(2021) Yi-Long Wu et al.   Journal of Thoracic Oncology

Medical Care Costs Associated with Cancer Survivorship in the United States

(2020) Angela B. Mariotto et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

(2020) Roy S. Herbst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

(2020) Yi-Long Wu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

(2019) Howard West et al.   LANCET ONCOLOGY

Current status of immune checkpoint inhibition in early-stage NSCLC

(2019) J Vansteenkiste et al.   ANNALS OF ONCOLOGY

Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS)

(2018) Stefan Andreas et al.   LUNG CANCER

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

EA5142 adjuvant nivolumab in resected lung cancers (ANVIL).

(2018) Jamie E. Chaft et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment Patterns and Health Resource Utilization Among Patients Diagnosed With Early Stage Resected Non–Small Cell Lung Cancer at US Community Oncology Practices

(2015) Philip O. Buck et al.   Clinical Lung Cancer

Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003

(2011) Lauren E. Cipriano et al.   VALUE IN HEALTH

Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

(2008) Jean-Pierre Pignon et al.   JOURNAL OF CLINICAL ONCOLOGY